Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include Fostamatinib (previously referred to as R788), an oral syk inhibitor that commenced its phase 3 clinical trial program (OSKIRA) for rheumatoid arthritis in 2010, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.